Jump to content

Page values for "Lisdexamfetamine"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringLisdexamfetamine (dimesylate)
brandStringVyvanse, Elvanse (EU)
structureFile
classesList of String, delimiter: ,[[:Category:Psychostimulants|Psychostimulant]] [[:Category:Amphetamines|Amphetamine]] [[:Category:ADHD medicines|ADHD medicine]] [[:Category:Schedule II controlled substances|Schedule II controlled substance]]
mechanismString'"`UNIQ--vote-00000013-QINU`"' Once converted, dextroamphetamine acts by displacing dopamine and norepinephrine from presynaptic vesicles via VMAT-2 and reversing DAT and NET transport, the shared mechanism of all amphetamine-class agents'"`UNIQ--ref-00000014-QINU`"'.
usesString'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"'
starting_doseStringADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day
preparationsStringCapsules 10, 20, 30, 40, 50, 60, 70 mg; chewable tablets 10, 20, 30, 40, 50, 60 mg
fda_maxString70 mg/day
pill_idText
routesList of String, delimiter: ,Oral
onsetString1-2 hours (slower than immediate-release amphetamine because activation requires enzymatic cleavage in red blood cells)
durationString10-12 hours (smoother profile than immediate-release amphetamine salts)
halflifeStringParent lisdexamfetamine <1 hour; dextroamphetamine 10-12 hours after release'"`UNIQ--ref-00000017-QINU`"'
bioavailabilityString~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"'
pregnancyStringLimited human data; the amphetamine class is associated with intrauterine growth restriction and neonatal withdrawal symptoms.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString[[USLegal:Schedule II|Schedule II controlled substance]] in US'"`UNIQ--ref-00000019-QINU`"'